Review Article
Recent Advances in Identifying Biomarkers and High-Affinity Aptamers for Gynecologic Cancers Diagnosis and Therapy
Table 1
Summary on biomarkers and aptamers with detection strategies.
| Gynaecological cancer | Biomarker | Aptamer type | Diagnosing method | Limit of detection | Advantage/disadvantage | Reference |
| Ovarian cancer | CA125 | DNA | Fluorescence quenching | 0.05 U/mL | Sensitive, need background optimization | [17] | Ovarian cancer | VEGF | DNA | Colorimetric assay | 185 pM | Less sensitive, visual detection | [18] | Cervical cancer | PTK-7 | DNA | RAMAN scattering | — | Need training personnel | [19] | Cervical cancer | PTK-7 | DNA | Cytosensor | 10-106 cells/mL | In vivo reflects real condition | [20] | Endometrial cancer | EGFR | RNA | Electrical | — | Sensitive, label free | [21] | Endometrial cancer | EGFR | DNA | Electro chemical | 50 pg/mL | Sensitive, consume more sample volume | [22] | Cervical cancer | HPV-16 E-7 | RNA | Radio isotope | Kd 1.9 µM | Sensitive, aptamer needs stabilization | [23] | Cervical cancer | HPV-16 | DNA | ELISA | — | Gold standard, less sensitive | [24] | Ovarian cancer | CA 125 | DNA | FET sensor | 5.0 × 10−9 U/mL | Sensitive, label free | [25] |
|
|